Uploaded July 2025 | Updated September 2026, 2 weeks ago
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
Abstract 310:
meetings.asco.org/abstracts-presentations/242151
Abstract 352:
meetings.asco.org/abstracts-presentations/242172
Abstract 382:
meetings.asco.org/abstracts-presentations/242239
Abstract 163:
meetings.asco.org/abstracts-presentations/242375
Abstract 178:
meetings.asco.org/abstracts-presentations/242481
0:57 What did Abstract 310 demonstrate about testosterone recovery?
4:14 What does Abstract 352 say concerning spot radiation in high-Gleason patients?
6:34 Encourage your loved ones to get tested
8:18 What does Abstract 382 have to say about PSA rise post-surgery?
10:50 Is there a minimum PSA level required for a PSMA scan to be effective?
12:05 According to Abstract 137, what effect do statins have on overall survival?
14:14 What did Abstract 163 say about preventing osteonecrosis of the jaw?
16:54 Did Abstract 178 find any curative benefit to Bipolar Androgen Therapy?
20:00 Alex's conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
Donate to PCRI: pcri.org/donate
For more information, visit pcri.org
Abstract 310:
meetings.asco.org/abstracts-presentations/242151
Abstract 352:
meetings.asco.org/abstracts-presentations/242172
Abstract 382:
meetings.asco.org/abstracts-presentations/242239
Abstract 163:
meetings.asco.org/abstracts-presentations/242375
Abstract 178:
meetings.asco.org/abstracts-presentations/242481
0:57 What did Abstract 310 demonstrate about testosterone recovery?
4:14 What does Abstract 352 say concerning spot radiation in high-Gleason patients?
6:34 Encourage your loved ones to get tested
8:18 What does Abstract 382 have to say about PSA rise post-surgery?
10:50 Is there a minimum PSA level required for a PSMA scan to be effective?
12:05 According to Abstract 137, what effect do statins have on overall survival?
14:14 What did Abstract 163 say about preventing osteonecrosis of the jaw?
16:54 Did Abstract 178 find any curative benefit to Bipolar Androgen Therapy?
20:00 Alex's conclusions
Don't know your stage? Take the quiz: visit prostatecancerstaging.org
To learn more about prostate cancer, visit pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join
Who we are:
The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
